Showing results (31-40 of 99) with videos related to

Sort By:
Pageof 10
Leukemia Research|December 4, 2012
Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS studyCarlos Besses, Jean-Jacques Kiladjian, Martin Griesshammer, et al.
Haematologica|December 18, 2009
High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrationsFrank Stegelmann, Lars Bullinger, Martin Griesshammer, et al.
European Journal of Haematology|October 31, 2021
Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patientsKai Wille, Karlo Huenerbein, Ellen Jagenberg, et al.
Haematologica|October 13, 2005
Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a phase II studyChristian Langer, Eva Lengfelder, Jürgen Thiele, et al.
Haematologica|October 29, 2017
Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety studyGunnar Birgegård, Carlos Besses, Martin Griesshammer, et al.
Blood|June 30, 2005
The Jak2V617F mutation, PRV-1 overexpression, and EEC formation define a similar cohort of MPD patientsPhilipp S Goerttler, Cordula Steimle, Edith März, et al.
Hamostaseologie|October 9, 2023
Arterial and Venous Thromboembolic Complications in 832 Patients with BCR-ABL-Negative Myeloproliferative NeoplasmsKai Wille, Eva Deventer, Parvis Sadjadian, et al.
Dermatology and Therapy|September 27, 2025
Aquagenic Pruritus Questionnaire: Predicting Myeloproliferative Neoplasms in Patients with Aquagenic PruritusFelix Witte, Elke Weisshaar, Martin Metz, et al.
Annals of Hematology|May 12, 2026
Prospective, non-interventional study of ruxolitinib therapy in patients with polycythaemia vera - German real-world data (PaVe study)Martin Griesshammer, Eyck von der Heyde, Rudolf Schlag, et al.
Annals of Hematology|August 31, 2021
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignanciesRohit Sekhri, Parvis Sadjadian, Tatjana Becker, et al.
Pageof 10